Evidence map›Paper›PMID 42132951›Full record

ArticleBriefings in bioinformatics2026

CEDR: robust consensus cancer subtyping with multi-omics data via ensemble dimensionality reduction.

Hongyan Cao, Zhaoyang Xu, Shilong Lin, Gang Du, Tong Wang, Juping Wang, Xiaoling Yang, Ruiling Fang, Yanhong Luo, Ping Zeng and 3 more

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hongyan CaoDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.ORCID 0000-0002-0315-7156
Zhaoyang XuDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Shilong LinDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Gang DuDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Tong WangDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Juping WangDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Xiaoling YangDepartment of Thoracic Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 Longcheng Street, Xiaodian District, Taiyuan, Shanxi 030032, PR China.
Ruiling FangDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Yanhong LuoDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Ping ZengDepartment of Biostatistics, School of Public Health, Xuzhou Medical University, No. 209 Tongshan Road, Yunlong District, Xuzhou, Jiangsu 221004, PR China.ORCID 0000-0003-2710-3440
Hongmei YuDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.
Yanbo ZhangDepartment of Health Statistics, Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, School of Public Health, Shanxi Medical University, No. 56 South Xinjian Road, Yingze District, Taiyuan, Shanxi 030001, PR China.ORCID 0000-0002-9461-4163
Yuehua CuiDepartment of Statistics and Probability, Michigan State University, 619 Red Cedar Road, East Lansing, MI 48824, United States.ORCID 0000-0001-8099-1753

Funding

Fundamental Research Program of Shanxi Province 202303021211130Michigan State UniversityMinistry of Education, China MEKLCEPP/SXMU-202415National Natural Science Foundation of China 82273742National Natural Science Foundation of China 82473739Open Project Fund from Key Laboratory of Coal Environmental Pathogenicity and PreventionShanxi Province Higher Education "Billion Project" Science and Technology Guidance ProjectShanxi Province Research Funding Project for Returned Overseas Scholars 2024-081
6 · The paper itself

Abstract

Cancer is a highly heterogeneous disease underpinned by complex molecular alterations. Accurate subtyping is critical for guiding personalized treatment and improving clinical outcomes. However, multi-omics data are high-dimensional, noisy, and heterogeneous across platforms, posing major challenges for reliable subtyping. To address this, dimensionality reduction is necessary to capture underlying molecular patterns in a low-dimensional space, facilitating both computational efficiency and biological interpretation. We present Consensus subtyping method with Ensemble Dimensionality Reduction for multi-omics data integration (CEDR), a consensus subtyping framework that integrates complementary linear and nonlinear dimensionality reduction methods with robust clustering and probabilistic ensemble modeling. Different from existing dimensionality reduction techniques, our framework adopts an ensemble learning framework that integrates multiple dimensionality reduction techniques with robust clustering to achieve reliable consensus cancer subtyping. We apply Optimally Tuned Robust Improper Maximum Likelihood Estimator to the concatenated low-dimensional matrix for robust subtyping, and ensemble the result with the Mixture Model for Clustering Ensembles to identify stable subtypes. Across extensive simulations, CEDR consistently outperformed conventional dimensionality reduction-based clustering, the Cluster Of Clusters Analysis (COCA) ensemble strategy, and state-of-the-art multi-omics integration algorithms (SNF and CIMLR) in both accuracy and robustness. Application to clear cell renal cell carcinoma and lower-grade glioma revealed biologically interpretable subtypes characterized by distinctive survival outcomes, pathway activities, and immune infiltration patterns. These findings demonstrate that CEDR provides a powerful and reliable strategy for multi-omics data integration and cancer subtyping, with strong potential for broader applications in high-dimensional multimodal data analysis.

Indexed as

Computational BiologyNeoplasmsAlgorithmsCluster AnalysisClustering AlgorithmsDimensionality ReductionEnsemble LearningHumansMultiomicscancer subtypingclustering ensembledimension reductionmulti-omics integrationrobust clustering

Identifiers

PMID42132951
PMCPMC13174402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.